---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-021120"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:06:56.774814+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# INmune Bio pipeline update: CORDStrom Phase 3 data and XPro1595 FDA alignment for Phase 2b/3 AD trial

## Summary
- CORDStrom Phase 3 shows improvements in itch, pain, and skin scores in RDEB; MAA submission expected Q3 2026 for UK.
- XPro1595 Phase 2 MINDFuL trial met FDA end-of-Phase 2 meeting; adaptive Phase 2b/3 design with CDR-SB primary accepted.
- CORDStrom potential TAM >$1.4B; annual COG $120-180K; anticipated reimbursement ~$700K per year.
- XPro1595 showed zero ARIA events in high-risk APOE4+ population; Phase 3 readiness targeted for 2027.
- CORDStrom regulatory milestones: RPDD and ODD approved, pre-MAA doc submitted, BLA/MAA submissions planned in 2026.

## SEC filing metadata
- accession: 0001213900-26-021120
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390026021120/0001213900-26-021120-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390026021120/ea02262026-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-021120
- JSON: https://secwatch.observer/filing/0001213900-26-021120.json
- Plain text: https://secwatch.observer/filing/0001213900-26-021120.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.